Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Shares Outstanding (Diluted Average) (2017 - 2026)

Champions Oncology (CSBR) has 13 years of Shares Outstanding (Diluted Average) data on record, last reported at $14.5 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 3.05% year-over-year to $14.5 million; the TTM value through Oct 2025 reached $14.5 million, up 3.05%, while the annual FY2025 figure was $14.3 million, 5.31% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $14.5 million in Q4 2025 per CSBR's latest filing, up from $13.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $14.6 million in Q2 2021 and bottomed at $13.4 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $13.9 million, with a median of $13.9 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 23.05% in 2021, then dropped 7.06% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $14.5 million in 2021, then dropped by 7.06% to $13.5 million in 2022, then rose by 0.06% to $13.5 million in 2023, then rose by 3.7% to $14.0 million in 2024, then grew by 3.05% to $14.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $14.5 million in Q4 2025, $13.8 million in Q3 2025, and $14.3 million in Q2 2025.